Research
The CD39/CD73 adenosinergic pathway is increased by proinflammatory states and modified by chemo-radiation in human non-small cell lung cancer
Cell Reports Medicine · By Kerryan Ashley, Alicia Ding, Mohammad Arammash, Krishna Iyer, Kishu Ranjan, Barani Kumar Rajendran, Boyu Huang, Daniel Boiarsky, Roy Herbst, Sarah Goldberg & Kurt A. Schalper ·
The Brief
- Researchers report that the adenosine-producing enzymes CD39 and CD73 are expressed locally in more than 85% of non-small cell lung cancers.
- The pathway is described as inducible and driven by proinflammatory states, and it is immunosuppressive.
- Expression is preferentially higher in lung adenocarcinomas with elevated tumour-infiltrating lymphocytes (TILs) and PD-L1, and chemo-radiation modifies the pathway.
Why it matters
The study links an inflammation-driven, immunosuppressive adenosine pathway to lung tumours and shows that chemo-radiation alters it, which bears on how tumour immunity is understood in this cancer.
Who’s affected
- cancer immunology and oncology researchers
- clinicians and scientists studying non-small cell lung cancer
- #lung cancer
- #adenosine
- #cd39
- #cd73
- #tumor immunology
- #chemoradiation
Ashley et al. report local expression of adenosine-producing enzymes CD39 and CD73 as an inducible and inflammation-driven immunosuppressive pathway present in >85% of NSCLCs. This pathway displays preferential expression in lung adenocarcinomas with elevated TILs and PD-L1 or in…
Timeline
Study published in Cell Reports Medicine
cell.com
The CD39/CD73 adenosinergic pathway is increased by proinflammatory states and modified by chemo-radiation in human non-small cell lung cancer